Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84207 | 1.00 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL11296165 | 0.81 | — | — | |
| SCHEMBL11750691 | 0.81 | — | — | |
| SCHEMBL20962970 | 0.75 | ALDH1A1 (0.58) | FFAR3 | |
| SCHEMBL4631111 | 0.75 | BACE1 (0.34) | — | |
| SCHEMBL3480750 | 0.75 | BACE1 (0.34) | — | |
| SCHEMBL472712 | 0.74 | ALDH1A1 (0.39) | FFAR3 | |
| SCHEMBL11296884 | 0.74 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL75520 | 0.71 | EP300 (0.41) | — | |
| SCHEMBL8019913 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | Aardvark Therapeutics, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-1718276-A2 | INHALANT FORMULATION CONTAINING SULFOALKYLETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | Cydex Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005065435-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. ET AL. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065651-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065649-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER Ϝ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1425311-A4 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1425311-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEMICAL COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054164-A1 | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials | EASTMAN CHEMICAL COMPANY (US) | 2004-03-18 | — | — | US | disclosed |
| US-6610671-B2 | Cyclodextrin derivatives for use in cosmetics, pharmacolog, cosmetic, or nutrients | EASTMAN CHEMICAL COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20020128468-A1 | Cyclodextrin sulfonates, guest inclusion complexes methods of making the same and related materials | BUCHANAN CHARLES M (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002055562-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | FFAR3 3580/4885 |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | FFAR3 1680/4885 |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | FFAR3 1680/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | FFAR3 4438/4885 |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | FFAR3 1680/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | FFAR3 821/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | FFAR3 2523/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | FFAR3 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.